Articles
Back in August 2017, UCLA researchers made headlines by discovering a new way to activate hair follicle stem cells. This was done through a metabolite called lactate. William Lowry and Heather Christofk of UCLA’s Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research were responsible for the lactate discovery. Lowry and Christofk…
Read MoreCEO of Follicum, Jan Alenfall, recently presented his company at the BioStock meeting which took place on April 29, 2019 in Stockholm, Sweden. The presentation details Follicum’s successes and plans for its diabetes and hair growth programs. Follicum’s hair growth program is composed of its peptide drug called FOL-005.The section discussing the hair growth program…
Read More
Yesterday, Replicel released a May 2019 Update which mentioned a new study using its dermal injector device to treat hair loss. The end of the press release states: “Over the next 18 months you should expect to see: new clinical data from a study completed showing the value of the dermal injector in treating hair…
Read MoreIt appears that the Shiseido trial results for Replicel’s RCH-01 will finally be revealed sometime around July 2019. In my post on WCHR 2019 Highlights a commenter named Neez shared this message: “Someone working on the rch-01 trial send this mail to a guy asking about the phase II results: Dear *****, The results will…
Read More
Once again, Follicle Thought is pleased to share some remarkable results from RiverTown Therapeutics’ RT1640. Precision Results The photos below include an alternate angle of a 6 month result which was previously shared in the RiverTown Game Changer article. This time an arrow has been added to the photo to indicate a birthmark for proper…
Read More
On April 24th-27th 2019 the 11th World Congress for Hair Research took place in Sitges, Barcelona. Usually, major announcements regarding the release of new treatments are not made at such conferences, however, worthwhile scientific information is typically shared. Importantly, companies who attend the WCHR are sometimes able to create business development opportunities. Below are some…
Read MoreSwedish biotechnology company Follicum announced yesterday it has filed a new patent application for its topical formulation of FOL-005. The news came via a press release on Follicum’s website. The press release mentions that: “With the new formulation, it will be possible to study several different doses and increase the dosage frequency in a simple…
Read More
Puretech Health, the parent company of Follica, has recently issued a 2018 Annual Report to shareholders which contains news about its long-standing hair growth company. New Proprietary Compounds Among the important Follica news shared in the Puretech Annual Report is the mentioning of “next-generation proprietary compounds.” Yes, that compounds with an “s”, as in more…
Read More
Today, Cassiopea SpA has announced topline data from its fully completed phase 2 dose ranging trial for men with androgenic alopecia. The results of the trial were favorable. Phase 2 Trial for Clascoterone The trial which was completed by Cassiopea included 400 men and 4 different doses of clascoterone, also known as breezula, for the…
Read More
As we continue to await a meaningful treatment becoming available and/or progressing in the clinical trial setting, I have more photo results from RiverTown Therapeutics Inc. to share. This result is a continuation of a previous before and after of a 60 yr old male that has been shared on Follicle Thought from RiverTown. This…
Read More